Grünenthal Expands US Presence with $250 Million Acquisition of Valinor Pharma and Movantik

1. Acquisition Details: Grünenthal has acquired Valinor Pharma and its commercial product Movantik for $250 million, marking a significant expansion of its US presence.
2. Product Portfolio: Movantik is a key product in Valinor Pharma's portfolio, which Grünenthal will now own globally.
3. US Growth Strategy: This acquisition is part of Grünenthal's ongoing strategy to strengthen its position in the US pharmaceutical market.
4. Financial Impact: The deal is valued at $250 million, with the potential to significantly boost Grünenthal's revenue and market share in the US.